Log in to save to my catalogue

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cogniti...

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cogniti...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_330336

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

About this item

Full title

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

Publisher

United States: John Wiley & Sons, Inc

Journal title

Alzheimer's & dementia, 2024-02, Vol.20 (2), p.1239-1249

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

INTRODUCTION
Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p‐tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited.
METHOD...

Alternative Titles

Full title

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_gup_ub_gu_se_330336

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_330336

Other Identifiers

ISSN

1552-5260,1552-5279

E-ISSN

1552-5279

DOI

10.1002/alz.13525

How to access this item